Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decoy20 in advanced solid tumors
NCT05651022Phase 2Active, not recruiting
- Sponsor
- Indaptus Therapeutics
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Decoy20 in hepatocellular carcinoma (HCC), colorectal cancer (CRC), urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (HNSCC), pancreatic adenocarcinoma (PDAC), sponsored by Indaptus Therapeutics. Started Feb 2023; status: active, not recruiting.
02
Drugs
Decoy20
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)urothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05651022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651022.